Effects of eNOS rs1799983 and ACE rs4646994 polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese patients with coronary heart disease.
The purpose of the present study was to clarify the association of eNOS 894G/T and ACE I/D genetic polymorphisms with the risk of coronary heart disease (CHD) and to explore the effects of these polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese CHD patients. In all, 153 CHD patients and 198 healthy controls were enrolled in the study. We collected 5 mL peripheral blood for DNA extraction. Genetic diagnosis of eNOS 894G/T was determined by direct sequencing. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect ACE I/D genotypes. We observed significant differences in the frequency distribution of eNOS and ACE polymorphisms between CHD patients and healthy controls (P < 0.05). Binary logistic regression stepwise analysis revealed that the genotypes had an additive and dominant effect on patients' therapeutic responses (P < 0.05). These data suggest that the genetic polymorphisms of ACE I/D and eNOS 894G/T probably play a role in the development of CHD and these genetic polymorphisms may affect the response to salvianolate injection in Chinese CHD patients.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacology, Central South University, Changsha, China; Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China.
Chao
C
Fang
Xian
X
Ren
Huan
H
Zhou
Zhi-Cheng
ZC
Gong
Li
L
Shen
Jing
J
Bai
Ji-Ye
JY
Yin
Jian
J
Qu
Xiang-Ping
XP
Li
Hong-Hao
HH
Zhou
Zhao-Qian
ZQ
Liu
D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D003327:Coronary Disease / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D010936:Plant Extracts / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D012306:Risk
D010936:Plant Extracts; C561960:salvianolate; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III; C488034:ACE protein, human; D007703:Peptidyl-Dipeptidase A
angiotensin converting enzyme; coronary heart disease; endothelial nitric oxide synthase; genetic polymorphism; salvianolate injection